Search
Oxycodegol
go.drugbank.com/drugs/DB14146InvestigationalLoxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263].
Ad5-nCoV
go.drugbank.com/drugs/DB15655Investigational[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalThe vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.
Rocatinlimab
go.drugbank.com/drugs/DB18809InvestigationalThe drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis.
Ifenprodil
go.drugbank.com/drugs/DB08954ApprovedInvestigationalWithdrawn[A220143, A196128] In an unbiased screen for compounds capable of reducing cell death induced by infection with the influenza strain H5N1, ifenprodil was found to have a protective effect against H5N1-
IGN311
go.drugbank.com/drugs/DB04988ExperimentalIGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.
Guvacine
go.drugbank.com/drugs/DB08848ExperimentalGuvacine is a pyridine alkaloid found in the Areca nut (also known as the Betel nut). It is an experimental drug with no approved indication. Experimental studies are still being investigated to determine all of the physiological effects...
REN-850
go.drugbank.com/drugs/DB05912ExperimentalREN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Cefovecin
go.drugbank.com/drugs/DB11505ExperimentalVet approvedIt is used for the treatment of skin infections caused by Pasturella multocida in cats, and Staphylococcus intermedius/S. canis in dogs.
Tandutinib
go.drugbank.com/drugs/DB05465InvestigationalThe use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.